Table 4.
Clinical characteristics and frequency of each type of immune-related adverse event in patients with non-small cell lung carcinoma and malignant melanoma
|
Characteristic
|
NSCLC, n = 209
|
MM, n = 130
|
| Age, yr | 66 ± 11 | 66 ± 13 |
| Sex, n (%) | ||
| Male | 143 (68.4) | 75 (57.7) |
| Female | 66 (31.6) | 55 (42.3) |
| BMI, kg/m2 | 21.7 ± 3.4 | 22.4 ± 4.3 |
| ECOG PS, n | ||
| 0-1 | 184 | 119 |
| 2-3 | 25 | 11 |
| Drugs, n (%) | ||
| Nivolumab | 61 (29.2) | 58 (44.6) |
| Pembrolizumab | 87 (41.6) | 35 (26.9) |
| Atezolizumab | 61 (29.2) | 0 (0.0) |
| Ipilimumab | 0 (0.0) | 27 (20.8) |
| Nivolumab + ipilimumab | 0 (0.0) | 10 (7.7) |
| History of ICI use, n (%) | 11 (5.3) | 34 (26.2) |
| Follow-up, d | 365 ± 335 | 466 ± 419 |
| Total irAEs, n (%) | ||
| GI-irAEs | 9 (4.3) | 13 (10.0) |
| Liver-irAEs | 7 (3.3) | 13 (10.0) |
| Lung-irAEs | 10 (4.8) | 11 (8.5) |
| Skin-irAEs | 9 (4.3) | 9 (6.9) |
| Thyroid-irAEs | 12 (5.7) | 9 (6.9) |
BMI: Body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; GI: Gastrointestinal; irAE: Immune-related adverse event; ICI: Immune checkpoint inhibitor; MM: Malignant melanoma; NSCLC: Non-small cell lung carcinoma.